Fibrotic remodeling in the NOD/ShiLtJ mouse model of Sjögren’s disease: insights from single-cell transcriptomics and AI-driven ECM quantification - Scorecard - MDSpire

Exploring Fibrotic Changes in the NOD/ShiLtJ Mouse Model of Sjögren’s Disease: Insights from Single-Cell Transcriptomics and AI-Enhanced ECM Analysis

  • By

  • Jennifer M. Morrissey

  • Deirdre A. Nelson

  • Li Chen

  • Mathieu Petitjean

  • Joey R. Tavarez

  • Amber L. Altrieth-Flagg

  • Nicholas L. Moskwa

  • Renae Williams-Atkinson

  • Ben Fowler

  • Rafael Pena

  • Kennedi Weston

  • Nikhita Kumar

  • Nathan Aist

  • Melinda Larsen

  • July 20, 2026

Share

Clinical Scorecard: Exploring Fibrotic Changes in the NOD/ShiLtJ Mouse Model of Sjögren’s Disease: Insights from Single-Cell Transcriptomics and AI-Enhanced ECM Analysis

At a Glance

CategoryDetail
ConditionSjögren's Disease (SjD)
Key MechanismsFibrosis and extracellular matrix (ECM) remodeling in salivary glands
Target PopulationPrimarily menopausal females with Sjögren's Disease
Care SettingResearch model for Sjögren's Disease

Key Highlights

  • NOD/ShiLtJ mouse model exhibits salivary gland fibrosis characteristic of SjD.
  • Fibroblast populations show increased ECM gene expression in affected glands.
  • Nintedanib treatment resulted in modest reductions in fibrotic indices.
  • Fibrosis severity correlates with diabetic phenotype and age.
  • Fibrosis is associated with salivary gland dysfunction in SjD.

Guideline-Based Recommendations

Diagnosis

  • Use the 2016 ACR–EULAR Classification Criteria for SjD diagnosis.

Management

  • Consider antifibrotic therapy with nintedanib for salivary gland dysfunction.

Monitoring & Follow-up

  • Assess salivary gland function and fibrosis as potential disease metrics.

Risks

  • Fibrosis is positively associated with focus scores and negatively correlated with gland function.

Patient & Prescribing Data

Patients with Sjögren's Disease experiencing salivary gland dysfunction.

Nintedanib shows potential as an antifibrotic treatment in SjD-related fibrosis.

Clinical Best Practices

  • Monitor for signs of fibrosis in SjD patients.
  • Evaluate the impact of antifibrotic therapies on salivary gland function.

Related Resources & Content

Original Source(s)

Related Content